Deciphera Pharmaceuticals Inc (OQ:DCPH)

Sep 18, 2020 07:00 am ET
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST) and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST. The mini-oral presentations, titled “Clinical Benefit with Ripretinib as ≥4th Line Treatment in Patients with Advanced Gastrointestinal Stromal Tumors (GIST): Update from the Phase 3 INVICTUS Study” and “Ripr
Sep 17, 2020 07:00 am ET
Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of data from the ovarian cancer cohort in Part 2 of the ongoing Phase 1b/2 study of rebastinib, the Company’s selective TIE2 inhibitor, in combination with paclitaxel and from Part 1 of the Phase 1b/2 study of rebastinib in combination with carboplatin. The E-poster presentations, titled “A phase 1b/2 study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer” and “A phase 1 study of rebastinib and carboplatin in patients with metastatic solid tumors,” were featured at the ESMO V
Aug 17, 2020 04:30 pm ET
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine kinase inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumor (GIST). The article, entitled "Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor (GIST): a phase 1 study of ripretinib," is now available
Aug 06, 2020 08:40 am ET
Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 9:00 AM ET. The conference will be held in a virtual meeting format.
Aug 04, 2020 04:05 pm ET
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical and corporate developments.
Jul 29, 2020 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020.
Jul 20, 2020 07:30 am ET
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
Zai Lab Limited (NASDAQ: ZLAB) and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ripretinib for the treatment of adult...
Jul 14, 2020 07:00 am ET
Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the Australian Therapeutic Goods Administration (TGA) has approved QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. The QINLOCK Marketing Authorisation Application was approved by the TGA under Project Orbis, an initiative of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence designed to provide a framework for c
Jul 02, 2020 04:01 pm ET
Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall survival (OS) for patients who crossed over to QINLOCK therapy following disease progression in the INVICTUS pivotal Phase 3 study. The INVICTUS study evaluated QINLOCK in adult patients with fourth-line gastrointestinal stromal tumor (GIST). The results were featured in an oral presentation at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal (GI) Cancer 2020 Virtual Meeting in a presentation ti
Jun 22, 2020 07:00 am ET
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib. The QINLOCK New Drug Submission was approved by Health Canada under Project Orbis, an initiative of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence designed to provide a framework for concurrent submission and review of oncol
Jun 11, 2020 07:00 am ET
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:40 PM ET. The conference will be held in a virtual meeting format.
Jun 08, 2020 07:30 am ET
Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that The Lancet Oncology has published results from the INVICTUS pivotal Phase 3 study of QINLOCK in patients with fourth-line gastrointestinal stromal tumor (GIST). The INVICTUS study met its primary endpoint, demonstrating a statistically significantly improvement in progression free survival (PFS) in patients randomized to QINLOCK compared with patients receiving placebo. The safety profile observed in INVICTUS was consistent with previously published results, and results from the study were previously presented at the Eur
May 29, 2020 08:05 am ET
Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2 clinical trial of rebastinib, the Company’s investigational orally administered, potent and selective inhibitor of the TIE-2 kinase, in combination with paclitaxel. The presentation, titled “An open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel in a dose expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer” (abstract 6085; poster 256), wil
May 29, 2020 08:00 am ET
Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of quality of life and certain safety results from the INVICTUS pivotal Phase 3 study evaluating QINLOCK™ (ripretinib) in adult patients with fourth-line advanced gastrointestinal stromal tumor (GIST). These results were presented as part of the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.
May 27, 2020 07:00 am ET
Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET. The conference will be held in a virtual meeting format.
May 15, 2020 06:34 pm ET
FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the U.S. Food and Drug Administration (FDA) has approved QINLOCK™ (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for QINLOCK and reviewed the New Drug Application (NDA) under the Real-Time Oncology Review (RTOR) pilot program. The QINLOCK NDA is also part of Project Orbis, an initiative of th
May 05, 2020 04:01 pm ET
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2020 and provided an update on clinical and corporate developments.
Apr 28, 2020 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5, 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020.
Mar 09, 2020 04:01 pm ET
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2019 and provided an update on clinical and corporate developments.
Mar 02, 2020 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call and Webcast on March 9, 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its fourth quarter and full year 2019 financial results on Monday, March 9, 2020.
Feb 20, 2020 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25 at 11:30 AM ET in New York.
Feb 19, 2020 04:01 pm ET
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 3,181,818 shares of the Company’s common stock at a price to the public of $55.00 per share were issued and sold in the offering. The gross proceeds to Deciphera from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. In addition, the Comp
Feb 13, 2020 10:12 pm ET
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its previously announced registered underwritten public offering of 3,181,818 shares of its common stock at a price to the public of $55.00 per share. The gross proceeds to Deciphera from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. The offering is expected to close on or about February 19, 2020, s
Feb 12, 2020 04:14 pm ET
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered underwritten public offering of $250.0 million in shares of its common stock. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to $37.5 million in shares of its common stock.
Feb 12, 2020 04:01 pm ET
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib, the Company’s investigational broad-spectrum KIT and PDGFRα inhibitor, for the treatment of patients with advanced gastrointe
Jan 13, 2020 09:00 am ET
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today provided a corporate update and highlighted key 2020 milestones in conjunction with its presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The Company will webcast its presentation today at 11:00 a.m. PT (2:00 p.m. ET) at
Jan 06, 2020 07:00 am ET
Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 11:00 AM PT in San Francisco.
Dec 16, 2019 07:00 am ET
Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ripretinib, the Company’s investigational broad-spectrum KIT and PDGFRα inhibitor, for the treatment of patients with advanced GIST who have received prior treatment with imatinib, sunitinib and regorafenib.
Dec 04, 2019 04:05 pm ET
Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appointed Ron Squarer to its Board of Directors. Mr. Squarer served as Chief Executive Officer and a member of the Board of Directors of Array BioPharma, Inc. (Arra
Nov 26, 2019 07:00 am ET
Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank S. Friedman to its Board of Directors. Mr. Friedman recently served as the global Chief Operating Officer of Deloitte Touche Tohmatsu Limited (Deloitt
Nov 13, 2019 04:30 pm ET
Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced preliminary data from the ongoing Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, including initial data in diffuse-type tenosynovial giant cell tumor (TGCT) patients as well as an encore presentation of the INVICTUS pivotal Phase 3 study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). Results from these programs will be presented at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting being held November 13-16 in Tokyo, Japan.
Nov 13, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that members of the management team will present at the following investor conferences:
Nov 04, 2019 04:01 pm ET
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the third quarter ended September 30, 2019 and provided a general update on clinical and corporate developments.
Oct 29, 2019 12:30 pm ET
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the presentation of updated results from its ongoing Phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with second-line through fourth-line plus GIST, as wel
Oct 28, 2019 12:30 pm ET
Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today presented data from its ongoing Phase 1b/2 clinical study of rebastinib, an oral TIE2 kinase inhibitor, in combination with paclitaxel at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. In addition, the Company also presented data from preclinical studies of DCC-3116, a potential first-in-class autophagy inhibitor to treat mutant RAS cancers.
Oct 28, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 4, 2019
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its third quarter 2019 financial results on Monday, November 4, 2019.
Oct 16, 2019 04:34 pm ET
Deciphera Pharmaceuticals to Present Data Updates From Portfolio of Kinase Switch Control Inhibitors in Four Poster Sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Can
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that data from four of the Company’s pipeline programs will be presented in poster sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be h
Oct 02, 2019 07:00 am ET
Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer
“We are thrilled to welcome Matt to the Deciphera team at this exciting time for our company,” said Steve Hoerter, President and Chief Executive Officer of Deciphera. “Matt’s deep expertise in successfully developing oncology therapeutics will be an incredible asset to Deciphera as we prepare the new drug application, or NDA, for ripretinib and advance our pipeline of novel product candidates. I look forward to working with Matt as we continue our mission to develop important new medicines for the treatment of cancer.”
Sep 30, 2019 09:06 am ET
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the late-breaking presentation of results from the INVICTUS pivotal Phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors (GIST) in an oral session at
Sep 25, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2 at 9:30 AM ET in New York City.
Sep 05, 2019 07:00 am ET
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that data from the Company’s INVICTUS pivotal Phase 3 study of ripretinib in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST) has been selected as an oral presentation at the European Society for Medical Oncology (ESMO) 2019 Congress to be held September 27 – October 1, in Barcelona, Spain.
Sep 03, 2019 04:01 pm ET
Deciphera Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 1,621,621 shares of the Company’s common stock at a price of $37.00 per share before underwriting discounts. The option exercise closed on September 3, 2019. On August 19, 2019, Deciphera announced the closing of its registered underwritten public offering in which 10,810,810 shares of the Comp
Aug 19, 2019 04:01 pm ET
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 10,810,810 shares of the Company’s common stock at a price to the public of $37.00 per share were issued and sold in the offering. The gross proceeds to Deciphera from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $400.0 million. In addition, the Com
Aug 14, 2019 10:43 pm ET
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its previously announced registered underwritten public offering of 10,810,810 shares of its common stock at a price to the public of $37.00 per share. The gross proceeds to Deciphera from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $400.0 million. The offering is expected to close on or about August 19, 2019, subject to custo
Aug 13, 2019 04:01 pm ET
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered underwritten public offering of $200.0 million in shares of its common stock. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to $30.0 million in shares of its common stock.
Aug 13, 2019 09:31 am ET
Thinking about buying stock in Canopy Growth, Deciphera Pharmaceuticals, Genworth Financial, JD.Com, or Tilray?
NEW YORK, Aug. 13, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, DCPH, GNW, JD, and TLRY....
Aug 13, 2019 07:05 am ET
Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today reported updated data from its ongoing Phase 1 clinical study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumors (GIST).
Aug 13, 2019 07:00 am ET
Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced positive top-line data from the INVICTUS pivotal Phase 3 clinical study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST).
Aug 02, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the second quarter ended June 30, 2019 and provided an update on clinical and corporate developments.
Jul 08, 2019 04:05 pm ET
Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors. Dr. Kelley will serve as an independent director and member of the Compensation Committee.
Jun 11, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, and Zai Lab Ltd. (NASDAQ: ZLAB), a China and U.S.-based innovative biopharmaceutical company,...
Jun 11, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, and Zai Lab Ltd. (NASDAQ: ZLAB), a China and U.S.-based innovative biopharmaceutical company, today announced an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical
Jun 10, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the addition of a new candidate to its pipeline, DCC-3116, a potential first-in-class small molecule designed to inhibit cancer autophagy, a key tumor survival mechanism. DCC-3116, discovered using the Company’s novel switch control inhibitor platform, is designed to inhibit autophagy by inhibiting the ULK kinase. Autophagy is a cellular pathway that has been shown to be upregulated in mutant RAS cancers and that also mediates resistance to inhibitors of the RAS signaling pathway.
May 30, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6 at 1:30 PM ET in New York City.
May 14, 2019 04:05 pm ET
Deciphera Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, May 20 at 9:00 AM ET at the Grand Hyatt New York.
May 09, 2019 04:05 pm ET
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical and corporate developments.
Mar 14, 2019 04:05 pm ET
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the fourth quarter and year ended December 31, 2018 and provided an update on clinical and corporate developments.
Mar 06, 2019 07:20 am ET
Market Trends Toward New Normal in Exelon, AT&T, United States Cellular, Deciphera Pharmaceuticals, Boyd Gaming, and Argo Group International — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Exelon Corporation (NYSE:EXC), AT&T Inc. (NYSE:T), United States Cellular...
Mar 04, 2019 04:05 pm ET
Deciphera Pharmaceuticals, Inc. Announces Retirement of Michael D. Taylor, Ph.D.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that after a successful tenure since 2014, Michael D. Taylor, Ph.D. will retire as President and Chief Executive Officer of the Company effective March 18, 2019, when Dr. Taylor will transition to senior advisor to the Company for six months; Dr. Taylor will also remain a member of the Company’s Board of Directors. Steve Hoerter, a current member of the Company’s Board of
Feb 07, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day on Thursday, February 14 at 3:30 PM ET at the St. Regis Hotel in New York.
Jan 03, 2019 07:30 am ET
Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has initiated an open-label, multicenter, Phase 1b/2 study of rebastinib, the Company’s investigational small molecule switch control inhibitor of TIE2 kinase, in combination with carboplatin in patients with advanced or metastatic solid tumors.
Jan 02, 2019 07:30 am ET
Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced positive, preliminary, top-line data from the ongoing dose escalation part of the Phase 1 clinical study with DCC-3014, the Company’s investigational small molecule switch control inhibitor of CSF1R, in patients with advanced malignancies. In addition, the Company announced a plan to expand the Phase 1 study to evaluate DCC-3014 in patients diagnosed with Tenosynovial Giant Cell
Jan 02, 2019 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael D. Taylor, Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 2:00 PM PT at the Westin St. Francis in San Francisco.
Dec 27, 2018 07:20 am ET
Report: Developing Opportunities within AutoZone, Deciphera Pharmaceuticals, Clearwater Paper, Churchill Downs, Whitestone REIT, and ZTO Express (Cayman) — Future Expectations, Projections Moving into
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AutoZone, Inc. (NYSE:AZO), Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH),...
Dec 19, 2018 07:13 pm ET
Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study)
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has initiated a pivotal Phase 3 clinical study, “INTRIGUE”, to evaluate the efficacy and tolerability of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRα inhibitor, compared to sunitinib in second-line gastrointestinal stromal tumor (GIST) patients.
Nov 20, 2018 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael D. Taylor, Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 2:30 PM ET at the Lotte New York Palace Hotel.
Nov 15, 2018 04:20 pm ET
Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced completion of enrollment in the INVICTUS pivotal Phase 3 clinical study evaluating the safety and efficacy of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in fourth-line and fourth-line-plus gastrointestinal stromal tumor (GIST) patients.
Nov 08, 2018 07:00 am ET
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the third quarter ended September 30, 2018 and provided an update on clinical and corporate developments.
Oct 23, 2018 08:35 am ET
New Research Coverage Highlights Griffon, SEACOR, Deciphera Pharmaceuticals, Clearwater Paper, Comtech Telecommunications, and United Natural Foods — Consolidated Revenues, Company Growth, and Expecta
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Griffon Corporation (NYSE:GFF), SEACOR Holdings, Inc. (NYSE:CKH),...
Oct 23, 2018 07:00 am ET
Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced today that it has initiated an open-label, multicenter, Phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety, tolerability, pharmacokinetics and efficacy in patients with advanced or metastatic solid tumors.
Oct 19, 2018 08:00 am ET
Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company’s broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST) as a proffered paper presentation at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
Sep 25, 2018 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00 PM ET at the InterContinental New York Barclay Hotel.
Sep 18, 2018 07:30 am ET
Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has appointed Daniel C. Martin as Chief Commercial Officer. In this...
Aug 29, 2018 07:55 am ET
Report: Exploring Fundamental Drivers Behind CIRCOR International, Duluth, Griffon, Despegar, SEACOR, and Deciphera Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CIRCOR International, Inc. (NYSE:CIR), Duluth Holdings Inc. (NASDAQ:DLTH),...
Aug 29, 2018 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Participate in Citi’s 13th Annual Biotech Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will participate in a panel discussion on targeted therapies in oncology at Citi’s 13th Annual Biotech Conference on Wednesday, September 5, 2018 at 3:15 PM ET at the Four Seasons Hotel Boston.
Aug 07, 2018 04:05 pm ET
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the second quarter ended June 30, 2018, and provided an update on recent clinical and corporate developments.
Aug 01, 2018 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 at 3:30 PM ET at the InterContinental Boston Hotel.
Jul 25, 2018 07:35 am ET
Analysis: Positioning to Benefit within Xylem, Duluth, Deciphera Pharmaceuticals, Mesabi Trust, Associated Banc-Corp, and AG Mortgage Investment Trust — Research Highlights Growth, Revenue, and Consol
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Xylem Inc. (NYSE:XYL), Duluth Holdings Inc. (NASDAQ:DLTH), Deciphera...
Jun 20, 2018 04:05 pm ET
Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced underwritten public offering, which closed on June 11, 2018, have exercised in full their option to purchase an additional 645,000 shares of Deciphera’s common stock. Including this option exercise, total gross proceeds to Deciphera from the offering of an aggregate 4,945,000 shares at a public offering price of $40.00 per share w
Jun 13, 2018 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the JMP Securities 2018 Life Sciences Conference on Wednesday, June 20, 2018 at 8:30 AM ET at the St. Regis in New York.
Jun 11, 2018 06:20 pm ET
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $40.00 per share for aggregate gross proceeds of $172 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock were offered by Deciphera.
Jun 06, 2018 10:31 pm ET
Deciphera Pharmaceuticals Announces Pricing of Public Offering
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of an underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $40.00 per share for aggregate gross proceeds of $172 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock are being offered by Deciphera. In addition, Deciphera granted the underwriters
Jun 04, 2018 04:12 pm ET
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has commenced a proposed public offering of 3,750,000 in shares of its common stock. In addition, Deciphera also intends to grant the underwriters a 30-day option to purchase up to 562,500 shares of its common stock.
Jun 02, 2018 09:30 am ET
Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated data from its ongoing Phase 1 clinical trial of DCC-2618, the company’s broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, in Chicago, Illinois and provided additional clinical and regulatory updates on DCC-2618.
May 29, 2018 08:30 am ET
Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has appointed Stephen B. Ruddy, Ph.D. as Chief Technical Officer. In this newly created role, Dr. Ruddy will be responsible for establishing and leading a world-class manufacturing and supply chain organization at Deciphera.
May 21, 2018 08:30 am ET
Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has elected Mr. Steven L. Hoerter, Chief Commercial Officer at Agios Pharmaceuticals, Inc., to its Board of Directors, effective as of May 17, 2018. Mr. Hoerter will serve as an independent director and a member of the Nominating and Corporate Governance Committee. The number of Deciphera directors was increased from eight to nine in connection with Mr. Hoerter’s election
May 18, 2018 07:35 am ET
Market Trends Toward New Normal in CPB, Deciphera Pharmaceuticals, Masonite International, First Internet, Duluth, and Virtus Investment Partners — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CPB Inc. (NYSE:CPF), Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH),...
May 14, 2018 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that members of the management team will present at the following upcoming investor conferences:
May 08, 2018 04:05 pm ET
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the first quarter ended March 31, 2018, and provided an update on recent clinical and corporate developments.
Apr 25, 2018 04:01 pm ET
Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual Meeting
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that an abstract highlighting DCC-2618, the Company’s KIT and PDGFRα inhibitor, has been selected for poster presentation and discussion at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 1-5, 2018 in Chicago, IL.
Apr 17, 2018 09:00 am ET
Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIS
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced pre-clinical data for DCC-2618 confirming a broad spectrum of potent inhibition across primary and secondary KIT mutations and primary PDGFRα mutations. Compared to the FDA approved and investigational compounds tested in this pre-clinical study, DCC-2618 demonstrated the broadest profile of inhibition of primary and secondary KIT mutations and primary PDGFRα mutations. The
Apr 16, 2018 08:00 am ET
Deciphera Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1 Clinical Trial of DCC-2618 at 2018 American Association for Cancer Research (AACR) Annual Meeting
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the presentation of updated data from its ongoing Phase 1 clinical trial of DCC-2618, the Company’s broad spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST). Filip Janku, M.D., Ph.D., Assistant Professor, The University of Texas MD Anderson Cancer Center presented the poster titled “Pharmacokinetic (PK), safety, and tolerability profile of
Mar 28, 2018 04:01 pm ET
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter 2017 Financial Results and Corporate Highlights
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the fourth quarter ended December 31, 2017 and provided an update on recent clinical and corporate developments.
Mar 23, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital — New Horizons, Emerging Trends, and Upco
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Goldfield Corp. (NYSE:GV), Dicerna Pharmaceuticals, Inc....
Mar 15, 2018 08:30 am ET
Deciphera Pharmaceuticals, Inc. to Report Clinical and Preclinical Data with DCC-2618 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that two abstracts highlighting DCC-2618, the Company’s KIT and PDGFRα inhibitor have been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.
Jan 24, 2018 08:15 am ET
Consolidated Research: 2018 Summary Expectations for ShotSpotter, Deciphera Pharmaceuticals, Ryman Hospitality Properties, Community Bank System, InfraREIT, and USANA Health Sciences — Fundamental Ana
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ShotSpotter Inc. (NASDAQ:SSTI), Deciphera Pharmaceuticals, Inc....
Jan 04, 2018 07:00 am ET
Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has initiated a Phase 3 clinical study to evaluate the safety and efficacy of DCC-2618, a pan-KIT and PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).
Jan 03, 2018 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael D. Taylor, Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 9:30 a.m. PT at the Westin St. Francis in San Francisco.
Dec 18, 2017 07:00 am ET
Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index
WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has been added to the Russell 2000® Index, as...
Nov 28, 2017 07:00 am ET
Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors
WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the European Medicines Agency (EMA) has granted orphan drug designation...
Nov 21, 2017 07:00 am ET
Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present...
Nov 20, 2017 07:00 am ET
Nov 14, 2017 10:00 am ET
Nov 14, 2017 07:00 am ET
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
-Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO- 
Nov 06, 2017 08:17 am ET
Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that an abstract highlighting the company’s pan-KIT and PDGFRα inhibitor, DCC-2618...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.